Hematological Oncology

Published by: Wiley Blackwell  

People

  1. Yahalom
    Yahalom
  2. Imber
    Imber
  3. Palomba
    Palomba
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Moskowitz
    Moskowitz
  7. Noy
    Noy
  8. Salles
    Salles
  9. Hamlin
    Hamlin
  10. Scordo
    Scordo

Groups

  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. Hematologic Malignancies, Division of (20)
  4. Radiation Oncology, Department of (20)
  5. Survivorship Research (20)
  6. Lymphoma (15)
  7. CTCR Scholars (10)
  8. Bone Marrow Transplant (9)
  9. Epidemiology and Biostatistics (8)
  10. GME, Radiation Oncology (8)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Joachim Yahalom"
Formats
  1. Meeting Abstract (20)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. Hematologic Malignancies, Division of (20)
  4. Radiation Oncology, Department of (20)
  5. Survivorship Research (20)
  6. Lymphoma (15)

More Groups

People
  1. Joachim Yahalom (20)
  2. Brandon Imber (10)
  3. Maria Palomba (10)
  4. Andrew Zelenetz (9)
  5. Alison Moskowitz (8)
  6. Anita Kumar (8)

More People

Years
  1. 2023 (11)
  2. 2021 (1)
  3. 2019 (5)
  4. 2017 (3)
Publishers
  1. Wiley Blackwell (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas
    Meeting Abstract

    Imber, B. S.; Yahalom, J.; Palomba, M. L.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H.; Figura, N.; Ladbury, C.; Keit, E. R.; Chew, J.; Fregonese, B.; Silverman, E. A.; Hajj, C.; Shah, G.; Kambhampati, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients
    Meeting Abstract

    Imber, B. S.; Tringale, K.; White, C.; Zhang, Z.; Scordo, M.; Yahalom, J.; Grommes, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; White, C.; Zhang, Z.; Grommes, C.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save

    • Hematological Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 02780232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell